Curiox Biosystems Co., Ltd (KOSDAQ:445680)
South Korea
· Delayed Price · Currency is KRW 94,000
+3,300 (3.64%)
At close: Apr 28, 2026
Curiox Biosystems Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Operating Revenue | 5,152 | 4,588 | 6,788 | 7,237 | 5,523 | Upgrade
|
| Other Revenue | - | - | - | -0 | - | Upgrade
|
| Revenue | 5,152 | 4,588 | 6,788 | 7,237 | 5,523 | Upgrade
|
| Revenue Growth (YoY) | 12.29% | -32.41% | -6.21% | 31.04% | 25.97% | Upgrade
|
| Cost of Revenue | 3,016 | 2,029 | 2,963 | 2,504 | 2,029 | Upgrade
|
| Gross Profit | 2,135 | 2,559 | 3,825 | 4,733 | 3,494 | Upgrade
|
| Selling, General & Admin | 10,075 | 11,654 | 10,626 | 13,217 | 10,129 | Upgrade
|
| Research & Development | 2,615 | 2,504 | 2,109 | 1,470 | 459.64 | Upgrade
|
| Amortization of Goodwill & Intangibles | 1,210 | 1,134 | 1,081 | 1,041 | 946.51 | Upgrade
|
| Other Operating Expenses | - | - | - | 41.27 | 23.69 | Upgrade
|
| Operating Expenses | 14,450 | 15,937 | 14,382 | 16,154 | 11,831 | Upgrade
|
| Operating Income | -12,314 | -13,378 | -10,557 | -11,421 | -8,337 | Upgrade
|
| Interest Expense | -1,189 | -702.03 | -25.7 | -2,777 | -1,704 | Upgrade
|
| Interest & Investment Income | 537.49 | 549.58 | 236.06 | 162.94 | 28.59 | Upgrade
|
| Currency Exchange Gain (Loss) | -81.15 | 1,433 | 117.78 | 42.83 | 338.5 | Upgrade
|
| Other Non Operating Income (Expenses) | -13,793 | 4,225 | 4.93 | 2,714 | -4,935 | Upgrade
|
| EBT Excluding Unusual Items | -26,840 | -7,873 | -10,224 | -11,278 | -14,609 | Upgrade
|
| Gain (Loss) on Sale of Assets | -68.44 | -123.27 | 13.02 | -12.11 | - | Upgrade
|
| Asset Writedown | -423.21 | - | - | - | -84.1 | Upgrade
|
| Pretax Income | -27,332 | -7,996 | -10,211 | -11,290 | -14,693 | Upgrade
|
| Income Tax Expense | -154.37 | 93.67 | -169.26 | 207.32 | -167.52 | Upgrade
|
| Earnings From Continuing Operations | -27,178 | -8,089 | -10,042 | -11,498 | -14,525 | Upgrade
|
| Minority Interest in Earnings | 0.84 | 0.47 | 1.28 | 3 | 1.31 | Upgrade
|
| Net Income | -27,177 | -8,089 | -10,040 | -11,495 | -14,524 | Upgrade
|
| Net Income to Common | -27,177 | -8,089 | -10,040 | -11,495 | -14,524 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 16 | 14 | 7 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 16 | 14 | 7 | 13 | Upgrade
|
| Shares Change (YoY) | 2.73% | 12.50% | 101.43% | -45.55% | - | Upgrade
|
| EPS (Basic) | -1645.00 | -503.00 | -702.41 | -1619.76 | -1114.48 | Upgrade
|
| EPS (Diluted) | -1645.00 | -503.00 | -702.41 | -1619.76 | -1114.50 | Upgrade
|
| Free Cash Flow | -11,245 | -9,956 | -8,376 | -10,711 | -5,387 | Upgrade
|
| Free Cash Flow Per Share | -680.67 | -619.10 | -585.95 | -1509.32 | -413.36 | Upgrade
|
| Gross Margin | 41.45% | 55.77% | 56.35% | 65.40% | 63.27% | Upgrade
|
| Operating Margin | -239.04% | -291.61% | -155.53% | -157.81% | -150.95% | Upgrade
|
| Profit Margin | -527.55% | -176.32% | -147.92% | -158.83% | -262.98% | Upgrade
|
| Free Cash Flow Margin | -218.29% | -217.02% | -123.39% | -148.00% | -97.54% | Upgrade
|
| EBITDA | -9,441 | -10,800 | -8,605 | -9,823 | -7,101 | Upgrade
|
| EBITDA Margin | -183.27% | -235.41% | -126.77% | -135.73% | -128.58% | Upgrade
|
| D&A For EBITDA | 2,873 | 2,578 | 1,952 | 1,598 | 1,236 | Upgrade
|
| EBIT | -12,314 | -13,378 | -10,557 | -11,421 | -8,337 | Upgrade
|
| EBIT Margin | -239.04% | -291.61% | -155.53% | -157.81% | -150.95% | Upgrade
|
| Advertising Expenses | 456.98 | 544.76 | 775.87 | 939.61 | 397.57 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.